Parkon® in the treatment of multiple sclerosis. A pilot study
<p>Multiple Sclerosis (MS) is one of the most common chronic demyelinating diseases of the central nervous system. The disease affects and relatively quickly leads to disability in mainly people 15-40 years of age. The development of MS can occur progressively or with exacerbations and remissi...
Saved in:
Main Authors: | Goldstein NI (Author), Golubev VL (Author), Goldstein RN (Author) |
---|---|
Format: | Book |
Published: |
Open Journal of Parkinson's Disease and Treatment - Peertechz Publications,
2020-08-07.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Parkon as a treatment of the Parkinson's disease
by: Golubev VL, et al.
Published: (2019) -
The results of a clinical and neurophysiological study of the effectiveness of Parkon spray in the treatment of Parkinson's Disease (PD)
by: Gekht BM, et al.
Published: (2022) -
Multi-center clinical study of Parkon® efficiency
by: Fjodorova NE, et al.
Published: (2021) -
Multiple Sclerosis: Perspectives in Treatment and Pathogenesis
Published: (2017) -
How does medicine Parkon® affect the MPTP-induced oxidation stress and MAO systems of the rats brain
by: N Goldstein, et al.
Published: (2021)